CN204133875U - Gastric floating type capsule containing hole - Google Patents
Gastric floating type capsule containing hole Download PDFInfo
- Publication number
- CN204133875U CN204133875U CN201420557881.2U CN201420557881U CN204133875U CN 204133875 U CN204133875 U CN 204133875U CN 201420557881 U CN201420557881 U CN 201420557881U CN 204133875 U CN204133875 U CN 204133875U
- Authority
- CN
- China
- Prior art keywords
- capsule
- apertures
- aerogenesis
- microgranule
- hole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 152
- 230000002496 gastric effect Effects 0.000 title abstract description 14
- 210000002784 stomach Anatomy 0.000 claims abstract description 50
- 239000004531 microgranule Substances 0.000 claims description 66
- 210000001589 microsome Anatomy 0.000 claims description 24
- 239000011241 protective layer Substances 0.000 claims description 9
- 210000004051 gastric juice Anatomy 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000002245 particle Substances 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 239000007789 gas Substances 0.000 abstract 4
- 239000011148 porous material Substances 0.000 abstract 3
- 230000000052 comparative effect Effects 0.000 description 18
- CKHJPWQVLKHBIH-ZDSKVHJSSA-N sulbutiamine Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(/C)=C(/CCOC(=O)C(C)C)SS\C(CCOC(=O)C(C)C)=C(\C)N(C=O)CC1=CN=C(C)N=C1N CKHJPWQVLKHBIH-ZDSKVHJSSA-N 0.000 description 12
- 229960003211 sulbutiamine Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000005188 flotation Methods 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 8
- 229960002873 benfotiamine Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 8
- 229950006836 fursultiamine Drugs 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 208000007107 Stomach Ulcer Diseases 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- -1 hydroxypropyl Chemical group 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 238000011017 operating method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- YRCWQPVGYLYSOX-UHFFFAOYSA-N synephrine Chemical compound CNCC(O)C1=CC=C(O)C=C1 YRCWQPVGYLYSOX-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical class CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940105623 neo-synephrine Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229960003684 oxedrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The utility model discloses a gastric floating type capsule containing holes, which comprises a capsule shell containing holes and a plurality of gas generating particles. The capsule shell with pores has 1-6 pores. The gas-producing particles are located in the capsule shell containing pores. According to the utility model discloses, can produce a large amount of gases behind the gas production particle contact gastric juice, make contain the inflation of hole capsule form balloon and float in the gastric juice top, and can increase stomach showy time by a wide margin, solve among the prior art stomach showy type preparation floating performance not good and the too high problem of manufacturing cost.
Description
Technical field
This utility model relates to a kind of apertures capsule of stomach float type.
Background technology
Stomach Floating type formulation is mainly according to fluid dynamic equilibrium principle design, and it can keep floating state under one's belt.The density of this type of preparation must control within the specific limits, makes its time floating under one's belt longer, and sustained release drugs.The advantage of stomach Floating type formulation be preparation can prolong drug in holdup time of gastric, be suitable for the medicine of drug absorption position at stomach, to improve the bioavailability of medicine, or utilize it to float on above gastric juice, can sustained release and act on stomach and gastric associated diseases as gastric ulcer and the cell migration of duodenal ulcer and the sterilization of stomach Helicobacter pylori for a long time.But in the art, stomach Floating type formulation (as microgranule or lozenge) has suddenly release or the not good problem of flotation property, too large, the production cost of individual difference of preparation release of active ingredients crosses the problems such as high.
Utility model content
The purpose of this utility model is the apertures capsule providing a kind of stomach float type, and it comprises apertures capsule shells and multiple aerogenesis microgranule being positioned at apertures capsule shells, and apertures capsule shells has 1-6 hole.Find by experiment, aerogenesis microgranule produces a large amount of gas after contact simulated gastric fluid, apertures capsule is expanded form balloon-like and float on above gastric juice, and significantly can increase the stomach flotation time, solve the not good problem too high with manufacturing cost of stomach Floating type formulation flotation property in prior art.In addition, relative to the general capsule of atresia, active component in apertures capsule can be poor by the Concentraton gradient between capsule and gastric juice, be discharged into gradually in gastric juice through hole, there is the effect delaying to discharge active ingredient, and the pressure that apertures capsule produces because aerogenesis expansion because of scalable capsule can delay rupture time and reduce preparation individual difference, can solve and cause active component to discharge suddenly because capsule breaks suddenly and rupture time diversity is large, and then cause and change the unmanageable problem of blood level.
An aspect of the present utility model is the apertures capsule providing this stomach float type, comprises apertures capsule shells and multiple aerogenesis microgranule.Apertures capsule shells has 1-6 hole.Aerogenesis microgranule is positioned at apertures capsule shells.
According to an embodiment of the present utility model, apertures capsule shells has 1-2 hole.
According to an embodiment of the present utility model, apertures capsule shells has head and body portion, and the quantity of hole is 1, and is positioned at the end of head or the end in body portion.
According to an embodiment of the present utility model, apertures capsule shells has head and body portion, and the quantity of hole is 2, and is positioned at the end of head and the end in body portion.
According to an embodiment of the present utility model, the diameter of each aerogenesis microgranule is greater than the diameter of each hole.
According to an embodiment of the present utility model, the diameter of each hole is less than or equal to 0.05mm.
According to an embodiment of the present utility model, the diameter of each aerogenesis microgranule is between 0.18mm to 2.00mm.
According to an embodiment of the present utility model, apertures capsule also comprises multiple non-aerogenesis microgranule, and it is positioned at apertures capsule shells.
According to an embodiment of the present utility model, non-aerogenesis microgranule is enteric-coated microsome.
According to an embodiment of the present utility model, apertures capsule also comprises protective layer coverage hole.
Comprehensively above-mentioned, this type of stomach flotation time of capsule containing 1 or 2 hole is 2.7 times of atresia capsule, can have speed concurrently and put the effect with slow release.Specifically, active component can discharge fast from the hole of apertures capsule, can be suspended in again in gastric juice at least 8 hours and just break.After the rupture, enteric-coated microsome disengages, and is subject to gastric emptying effect and enters intestinal.Thus, relative to the general capsule containing enteric-coated microsome, this type of capsule can extend the emission and absorption time of more than 8 hours.Above-mentioned utility model content aims to provide the simplification summary of present disclosure, possesses basic understanding to make reader to present disclosure.This utility model content is not the complete overview of present disclosure, and its purpose is not being pointed out the key/critical element of this utility model embodiment or defining scope of the present utility model.After consulting following description, those skilled in the art belonging to this utility model can understand the technological means and enforcement aspect that essence spirit of the present utility model and this utility model adopt easily.
Accompanying drawing explanation
Figure 1A-1D is the schematic diagram of the apertures capsule according to this utility model several implementations.
Fig. 2 is the graph of a relation of the fursultiamine concentration vs. time of comparative example 1 and experimental example 1-3.
Fig. 3 is the graph of a relation of the benfotiamine concentration vs. time of comparative example 2 and experimental example 4-6.
Fig. 4 is the graph of a relation of the sulbutiamine concentration vs. time of comparative example 3 and experimental example 7-9.
Detailed description of the invention
In order to make describing of present disclosure more detailed and complete, hereafter have been directed to enforcement aspect of the present utility model and detailed description of the invention proposes illustrative description; But this not implements or uses the unique forms of this utility model detailed description of the invention.Each embodiment disclosed below, can mutually combine or replace, also can add other embodiment in one embodiment, and need not further record or illustrate useful when.
In the following description, following embodiment is fully understood describing many details in detail to enable reader.But, can when putting into practice embodiment of the present utility model without when these specific detail.In other cases, for simplifying accompanying drawing, the structure known only is depicted schematically in figure.
An aspect of the present utility model provides a kind of apertures capsule of stomach float type.Figure 1A display is according to the schematic diagram of the apertures capsule of the stomach float type of this utility model embodiment.Apertures capsule can be the capsule of hard capsule, soft capsule or other kinds.As shown in Figure 1A, apertures capsule comprises apertures capsule shells 10 and multiple aerogenesis microgranule 20 being positioned at apertures capsule shells 10.Apertures capsule shells 10 has head 12 and body portion 14, and the mutual fit of head 12 and body portion 14 is to form enclosed space.Because apertures capsule must be floating several more than dozens of hour under one's belt, so the material of apertures capsule shells 10 must have good ductility, crushing resistance, hygroscopicity and possess suitable thickness, to avoid apertures capsule fast softening and breaking under one's belt.In several embodiment, the thickness of apertures capsule shells 10 is between 0.11-0.115mm.In several embodiment, the material of apertures capsule shells 10 comprises gelatin, corn starch, hydroxypropyl emthylcellulose or above-mentioned combination in any, but is not limited thereto.
Apertures capsule shells 10 has one or more hole 10a.Hole 10a penetrates apertures capsule shells 10, can be released into the external world fast to allow inner active component.Such as can get out hole 10a to prepare apertures capsule shells 10 in capsule shells.Bore mode such as using prong to pierce through capsule shells or utilize the special mould that burrows to form hole 10a, but is not limited thereto.The shape of hole 10a can be such as circular, oval or other shapes, is also not limited thereto.It should be noted that too much hole will cause apertures capsule break ahead of time in gastric juice and reduce the stomach flotation time.Therefore, the number of hole 10a the rate of release of active component according to demand and stomach flotation time must do suitable selection.
Known in following example, apertures capsule shells 10 preferably has 1-6 hole.Figure 1A-1C shows the schematic diagram according to the apertures capsule of this utility model several implementations.As shown in Figure 1A, the quantity of hole 10a is 1, and is positioned at the end of head 12.Certainly, in other embodiments, hole 10a also can be positioned at the end in body portion 14.As shown in Figure 1B, the quantity of hole 10a is 2, and is positioned at the end of head 12 and the end in body portion 14.As shown in Figure 1 C, apertures capsule shells 10 has 6 hole 10a, and lay respectively at the end of head 12, the end in body portion 14 and the side in head 12 and body portion 14, its major axis along apertures capsule arranges and surrounds into ring-type.Certainly, the position of above-mentioned hole 10a also can convert arbitrarily, to allow apertures capsule keep poised state under one's belt as far as possible, so the position of hole 10a is not limited to illustrated in Figure 1A-1C.
Aerogenesis microgranule 20 is positioned at apertures capsule shells 10.Can there is chemical reaction and release gas (as carbon dioxide) in aerogenesis microgranule 20, and apertures capsule is floated in gastric juice after contact gastric acid.Specifically, because apertures capsule has hole 10a, so apertures capsule is after entering stomach, gastric juice can enter in apertures capsule through hole 10a, react with aerogenesis microgranule 20 and form gas, therefore apertures capsule can undergoes rapid expansion at short notice, forms the structure of similar balloon, and be easy to float in stomach, significantly increase the stomach flotation time.If the stomach flotation time of apertures capsule is longer, the composition that duodenum and jejunum front end for stomach or stomach near-end absorb has better absorption, and the bioavailability of active component will significantly improve; Or utilize it to float on above gastric juice, can sustained release and act on the sterilization as the antacid of gastric ulcer and duodenal ulcer and pain relieving, cell migration and stomach Helicobacter pylori of stomach and gastric associated diseases for a long time.In addition, the stomach flotation time increases, and also can promote the stripping quantity of the active component of indissoluble.
Alkaline matter can be comprised in the composition of aerogenesis microgranule 20.Alkaline matter, as sodium bicarbonate, after contact gastric acid, can react and aerogenesis (such as forming carbon dioxide) with gastric acid.After gas-forming reaction occurs, that can accelerate aerogenesis microgranule 20 collapses loose speed, promote the water soluble ingredient in aerogenesis microgranule 20 or liposoluble constituent molten from, in capsule, form high concentration gradient, then be diffused in gastric juice through hole.In one embodiment, the alkaline matter in aerogenesis microgranule 20 comprises sodium bicarbonate, potassium bicarbonate, sodium carbonate, calcium carbonate or its combination, but is not limited thereto.In a detailed description of the invention, aerogenesis microgranule 20 comprises alkaline matter, and the percentage by weight of alkaline matter is the 0.5-20wt% of aerogenesis microgranule 20 gross weight.Certainly, aerogenesis microgranule 20 also can comprise acidic materials, as ascorbic acid (vitamin) C, still can produce gas to be used in gastric juice pH-value (pH value) when partial neutral.But in the ordinary course of things, acidic materials and alkaline matter must be isolated (such as distinguishing pelletize and coating film clothing by granulates and alkali granule), make aerogenesis microgranule 20 possess stability in storage.But the acidity in this type of aerogenesis microgranule 20 and alkaline matter can under specific condition (such as relative humidity be greater than 80% or water enter in capsule) make its acid contact with each other with alkali stripping and produce gas.The ratio of acidic materials and alkaline matter and consumption can do any adjustment, and this ratio and consumption, also can in order to adjust the pH value of gastric juice except determining except gas yield.
On the other hand, in the composition of aerogenesis microgranule 20, also can comprise diluent, as microcrystalline Cellulose, lactose, sucrose, glucose, calcium carbonate, calcium phosphate, starch or its combination, but be not limited thereto.In addition, in the composition of aerogenesis microgranule, also active component can be comprised, as short-acting type medicine, as fursultiamine (fursultiamine), benfotiamine (benfotiamine), sulbutiamine (sulbutiamine); Act on stomach and duodenal medicine, as antibiotic, polypeptide, amino acid, antioxidant, acidproof probiotic bacteria, mucosa consolidant; At the active component that gastric acid dissolubility is higher, as ephedrine class edge thing, Neosynephrine element (synephrine) etc.
It should be noted that as shown in Figure 1A, the diameter D1 of aerogenesis microgranule 20 need be greater than the diameter D2 of hole 10a, is scattered to the external world by hole 10a to avoid aerogenesis microgranule 20.In several detailed description of the invention, the diameter D2 of hole 10a is less than or equal to 0.05mm.In several detailed description of the invention, the diameter D1 of each aerogenesis microgranule 20 is between 0.18mm to 2.00mm.But above-mentioned size range is only for illustrating, but not be used for limiting this utility model.
In addition, in several embodiment, apertures capsule also comprises multiple non-aerogenesis microgranule 30, and it is positioned at apertures capsule shells 10, as shown in Figure 1B-1C.For example, non-aerogenesis microgranule 30 such as can be enteric-coated microsome, and it can comprise enteric film clothing (not shown) and be coated on its surface.Enteric film clothing can not dissolve at stomach, but can dissolve under the certain ph scope of the intestinal (as small intestinal or large intestine) for effect.The material of enteric film clothing can be such as cellulose derivative, acrylic copolymer, maleic acid, polythene derivative etc.In a detailed description of the invention, enteric film clothing is Eugragit
tM30D-55 (trade name).Enteric-coated microsome can disengage after apertures capsule shells 10 is broken, and enters duodenum by pylorus, then enters small intestinal and large intestine according to the order of sequence.Under the intestinal environment for effect, the enteric film clothing on enteric-coated microsome surface starts to dissolve, and disengages the active component in enteric-coated microsome.Therefore, the apertures capsule of present embodiment except applicablely acting on stomach, near-end intestines and stomach such as duodenum and jejunum front end and the aforementioned intestines and stomach position of stomach have the active component preferably absorbed, associated uses comprises the gastric acid neutralization for the treatment of gastric and duodenal ulcers, stomach Helicobacter pylori infects, gastric mucosa and duodenal mucosa healing; Act on nerve between intestinal thus the similar victory peptide of the glycemic element of the active component of appetite-suppressing as oral (Glucagon like pepetide); The preferred active component that stomach absorbs is as weak acid drugs aspirin (Aspirin).
In one embodiment, apertures capsule comprises aerogenesis microgranule 20 and non-aerogenesis microgranule 30 (as enteric-coated microsome), and aerogenesis microgranule 20 and non-aerogenesis microgranule 30 all comprise active component.This kind of apertures capsule can be floating for a long time under one's belt, aerogenesis microgranule 20 contacted with gastric juice and collapses fast and loose discharge active component, and making non-aerogenesis microgranule 30 in follow-up gastrointestinal tract, just disengage active component, so can reach the effect discharged for a long time.For example, total release time can reach more than 18 hours, even can reach more than 24 hours.
In another embodiment, as shown in figure ip, apertures capsule also can comprise protective layer 40 coverage hole 10a.Because hole 10a penetrates apertures capsule shells 10, make inner aerogenesis microgranule 20 can contact extraneous environment, be therefore preferably formed protective layer 40 coverage hole 10a.In one embodiment, the material of protective layer 40 can be dissolved by gastric juice, and hole 10a is exposed; The material of this type of protective layer 40 is such as polyacrylic resin.In another embodiment, namely aerogenesis microgranule 20 enters in capsule at liquid the environment producing acidic aqueous solution starts to produce gas, then destroys protective layer 40 by gas pressure, hole 10a is exposed; Be the polymer fatty acid of solid under the material such as room temperature of this type of protective layer 40, as cocoa butter.
Example
Below enumerate several example to go back elaboration method of the present utility model, so it is only the use illustrated, and is not used for limiting this utility model, and protection of the present utility model limited by claims and equivalents thereof.
Example 1
There is provided a kind of aerogenesis microgranule containing active component, it consists of 10wt% fursultiamine, 5wt% Verdoflavin, 5wt% sodium bicarbonate and 80wt% excipient (being mainly microcrystalline Cellulose).The diameter of the aerogenesis microgranule of the present embodiment is 0.8-1.0mm.There is provided four No. 0 capsules in addition, be respectively atresia capsule, apertures capsule containing 1,2 and 6 hole, hole location please refer to Figure 1A-1C.Hole is formed with prong puncture capsule, and its diameter is less than or equal to 0.05mm.Subsequently, by above-mentioned aerogenesis microgranule filling so far four No. 0 capsules, the loading of aerogenesis microgranule is 500mg.Aerogenesis microgranule collocation atresia capsule person called after comparative example 1, aerogenesis microgranule is arranged in pairs or groups respectively containing the apertures capsule person called after experimental example 1,2 and 3 according to the order of sequence of 1,2,6 hole.
Subsequently, inserted in the beaker containing 250ml simulated gastric fluid (pH is about 3.0) by the capsule of comparative example 1, experimental example 1,2 and 3, and stir with Magnetitum between 21-25 DEG C, Magnetitum rotating speed is 180 beats/min.After inserting simulated gastric fluid, the capsule deliquescing gradually of comparative example 1, at about 30 minutes because gastric acid invades, microgranule starts aerogenesis and expands gradually.But the capsule of experimental example 1-3 expanded gradually in 3 minutes, form floating balloon, and frequently have bubble to expose.And the visible flavous Verdoflavin stripping of naked eyes.The original capacity of No. 0 capsule is about 680mL, and after aerogenesis microgranule aerogenesis, the capsule of experimental example 1-3 can be expanded to about 3 times of original volume.Finally, the capsule of experimental example 3 broke after 200 minutes, and the capsule of comparative example 1 broke after 240 minutes, and the capsule of experimental example 1-2 broke after 480 minutes.That is, less hole can extend the capsule time floating under one's belt.
In addition, analyze under different time points with high-performance liquid chromatograph (HPLC), the change of fursultiamine concentration in simulated gastric fluid.The graph of a relation of fursultiamine concentration and time as shown in Figure 2.In fig. 2, fursultiamine molten from the capsule of speed far above comparative example 1 of the capsule of visible experimental example 1-3.Infer because gastric juice infiltrates in apertures capsule through hole, form inside and outside concentration difference, cause fursultiamine fast by capsule internal diffusion to outside capsule.
Example 2
A kind of aerogenesis microgranule and a kind of enteric-coated microsome are provided: aerogenesis microgranule consist of 10wt% benfotiamine, 5wt% Verdoflavin, 5wt% sodium bicarbonate and 80wt% excipient (being mainly microcrystalline Cellulose); Enteric-coated microsome consist of 10wt% benfotiamine, 5wt% Verdoflavin and 85wt% excipient (being mainly microcrystalline Cellulose), and coated with enteric film clothing.Enteric film clothing coating solution is Eugragit
tM30D-55.The aerogenesis microgranule of the present embodiment and the diameter of enteric-coated microsome are all 0.8-1.0mm.Four No. 0 capsules are provided in addition, are respectively atresia capsule, apertures capsule containing 1,2 and 6 hole, its preparation method and architectural feature identical with example 1.Then by above-mentioned two kinds of microgranules filling so far four No. 0 capsules, the loading of aerogenesis microgranule and enteric-coated microsome is respectively 150mg and 350mg.Microgranule collocation atresia capsule person called after comparative example 2, microgranule is arranged in pairs or groups respectively containing 1,2,6 hole capsule person called after experimental example 4,5 and 6 according to the order of sequence.
Subsequently, to be same as the atresia capsule of operating procedure process comparative example 2 and the apertures capsule of experimental example 4-6 of example 1.After inserting simulated gastric fluid, the capsule deliquescing gradually of comparative example 2, expanded gradually at about 30 minutes.But the capsule of experimental example 4-6 expanded gradually in 3 minutes, form floating balloon, and frequently have bubble to expose.In addition, observed some particles aerogenesis and collapsed and fallen apart for comparatively fine powder, be judged as aerogenesis microgranule; Another part microgranule is also uninfluenced, is judged as enteric-coated microsome.Finally, the capsule of experimental example 6 breaks about after 180 minutes, and the capsule of comparative example 2 broke after 240 minutes, and the capsule of experimental example 4-5 broke after 480 minutes.Therefore, less hole can extend the capsule floating time.
In addition, analyze under different time points with HPLC, the change of benfotiamine concentration in simulated gastric fluid.The graph of a relation of benfotiamine concentration and time as shown in Figure 3.In figure 3, the benfotiamine of the apertures capsule of visible experimental example 4-6 is molten from the atresia capsule of speed a little more than comparative example 2.
Comprehensively above-mentioned, this type of capsule containing 1 or 2 hole can have speed concurrently and put the effect with slow release.Specifically, this type of capsule can rapid release of active composition under one's belt, can be suspended in again in gastric juice at least 8 hours and just break.After the rupture, enteric-coated microsome disengages, and is subject to gastric emptying effect and enters intestinal.Thus, relative to the general capsule containing enteric-coated microsome, this type of capsule can improve the emission and absorption time of more than 8 hours.
Example 3
A kind of constituent of sulbutiamine powder, a kind of aerogenesis microgranule and a kind of enteric-coated microsome are provided.The constituent of sulbutiamine powder consist of 20wt% sulbutiamine, 5wt% Verdoflavin and 75wt% excipient (being mainly microcrystalline Cellulose).Aerogenesis microgranule consist of 20wt% sulbutiamine, 5wt% Verdoflavin, 5wt% sodium bicarbonate and 70wt% excipient (being mainly microcrystalline Cellulose).Enteric-coated microsome consist of 20wt% sulbutiamine, 5wt% Verdoflavin and 75wt% excipient (being mainly microcrystalline Cellulose), and coated with enteric film clothing.Enteric film clothing coating solution is Eugragit
tM30D-55.The diameter of sulbutiamine powder is about 0.8-1.0mm.The diameter of aerogenesis microgranule and enteric-coated microsome is all 0.8-1.0mm.Then be filled to respectively by above-mentioned sulbutiamine powder not containing hole and the capsule containing 1 hole, respectively called after comparative example 3 and experimental example 7, loading is 500mg.In addition above-mentioned aerogenesis microgranule and enteric-coated microsome are filled to the capsule containing 1 and 2 hole respectively, respectively called after experimental example 8 and 9, the loading of aerogenesis microgranule and enteric-coated microsome is respectively 150mg and 350mg.
Subsequently, to be same as the atresia capsule of operating procedure process comparative example 3 and the apertures capsule of experimental example 7-9 of example 1.After inserting simulated gastric fluid, the powder atresia capsule of comparative example 3 broke at about 40 minutes.The powder apertures capsule of experimental example 7 and the Microdot Capsule of experimental example 8-9, owing to having hole, therefore just expanded gradually, form floating balloon in 3 minutes, and frequently exposed bubble and release Verdoflavin.In addition, observe in the Microdot Capsule of experimental example 8-9 to have some particles aerogenesis and collapse and fall apart for comparatively fine powder, be judged as aerogenesis microgranule; Another part microgranule is also uninfluenced, is judged as enteric-coated microsome.Finally, the Sprinkle Caps of comparative example 3 and experimental example 7 main body about 180 minutes time is broken.The Microdot Capsule of experimental example 8-9 just broke after 480 minutes.
In addition, analyze under different time points with HPLC, the change of sulbutiamine concentration in simulated gastric fluid.The graph of a relation of sulbutiamine concentration and time as shown in Figure 4.In the diagram, the active component of the Microdot Capsule of visible experimental example 8-9 is molten from the Sprinkle Caps of speed higher than comparative example 3 and experimental example 7.Infer because the Sprinkle Caps of experimental example 7 is without inner aerogenesis pressure-driven, so active component release rate is comparatively slow.
Comprehensively above-mentioned, this type of stomach flotation time of capsule containing 1 or 2 hole is 2.7 times of atresia capsule, can have speed concurrently and put the effect with slow release.Specifically, active component can discharge fast from the hole of apertures capsule, can be suspended in again in gastric juice at least 8 hours and just break.After the rupture, enteric-coated microsome disengages, and is subject to gastric emptying effect and enters intestinal.Thus, relative to the general capsule containing enteric-coated microsome, this type of capsule can extend the emission and absorption time of more than 8 hours.
Although this utility model with embodiment openly as above; so it is not used for limiting this utility model; any those skilled in the art; not departing from spirit and scope of the present utility model; can do various different selection and amendment, therefore protection domain of the present utility model limited by claims and equivalents thereof.
Claims (10)
1. an apertures capsule for stomach float type, is characterized in that, the apertures capsule of described stomach float type comprises:
Apertures capsule shells, it has 1-6 hole; And
Multiple aerogenesis microgranule, it is positioned at described apertures capsule shells.
2. the apertures capsule of stomach float type as claimed in claim 1, it is characterized in that, described apertures capsule shells has 1-2 hole.
3. the apertures capsule of stomach float type as claimed in claim 1, it is characterized in that, described apertures capsule shells has head and body portion, and the quantity of described hole is 1, and is positioned at the end of described head or the end in described body portion.
4. the apertures capsule of stomach float type as claimed in claim 1, it is characterized in that, described apertures capsule shells has head and body portion, and the quantity of described hole is 2, and is positioned at the end of described head and the end in described body portion.
5. the apertures capsule of stomach float type as claimed in claim 1, it is characterized in that, the diameter of each described aerogenesis microgranule is greater than the diameter of each described hole.
6. the apertures capsule of stomach float type as claimed in claim 1, it is characterized in that, the diameter of each described hole is less than or equal to 0.05mm.
7. the apertures capsule of stomach float type as claimed in claim 1, it is characterized in that, the diameter of each described aerogenesis microgranule is between 0.18mm to 2.00mm.
8. the apertures capsule of stomach float type as claimed in claim 1, it is characterized in that, the apertures capsule of described stomach float type also comprises multiple non-aerogenesis microgranule, and described multiple non-aerogenesis microgranule is positioned at described apertures capsule shells.
9. the apertures capsule of stomach float type as claimed in claim 8, it is characterized in that, described multiple non-aerogenesis microgranule is enteric-coated microsome.
10. the apertures capsule of stomach float type as claimed in claim 1, it is characterized in that, the apertures capsule of described stomach float type also comprises protective layer, and described protective layer covers described hole.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW103200848U TWM485044U (en) | 2014-01-15 | 2014-01-15 | Gastric-floating-type hole-containing capsule |
| TW103200848 | 2014-01-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN204133875U true CN204133875U (en) | 2015-02-04 |
Family
ID=51943804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201420557881.2U Expired - Fee Related CN204133875U (en) | 2014-01-15 | 2014-09-26 | Gastric floating type capsule containing hole |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN204133875U (en) |
| TW (1) | TWM485044U (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105878213A (en) * | 2015-01-26 | 2016-08-24 | 美佳胜肽科技股份有限公司 | Perforated capsule case for sublingual absorption and sublingual absorption type capsule |
| TWI645865B (en) * | 2015-01-26 | 2019-01-01 | 美佳胜肽科技股份有限公司 | Hole-containing capsule shell for sublingual absorption and sublingual absorption capsule |
-
2014
- 2014-01-15 TW TW103200848U patent/TWM485044U/en not_active IP Right Cessation
- 2014-09-26 CN CN201420557881.2U patent/CN204133875U/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| TWM485044U (en) | 2014-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2545399C (en) | Protein-polysaccharide microcapsules for delivering active agents to the gi tract | |
| Dey et al. | Multiparticulate drug delivery systems for controlled release | |
| US6030641A (en) | Sustained release capsule and method for preparing the same | |
| AU774957B2 (en) | Hydrodynamically balancing oral drug delivery system | |
| Palugan et al. | Coated pellets for oral colon delivery | |
| Ciper et al. | Modified conventional hard gelatin capsules as fast disintegrating dosage form in the oral cavity | |
| RO121674B1 (en) | Enteric coated pharmaceutical composition and process for preparing the same | |
| CN101507718B (en) | Sodium rabeprazole enteric-coated orally disintegrating tablets and preparation method thereof | |
| EP2289496A3 (en) | Non-gelatin soft capsule system | |
| CN204133875U (en) | Gastric floating type capsule containing hole | |
| EA014825B1 (en) | Method for stabilising pharmaceutical administration forms that contain micro-organisms | |
| US11511092B2 (en) | Automatic drug delivery device | |
| ES2224642T3 (en) | ADMINISTRABLE COMPOSITIONS BY ORAL ROUTE, WHICH INCLUDE A POLYACARIDE RETICULATED BY A CARTON AND A DIGERABLE POLYMER IN THE LOWER GASTROINTESTINAL TRACT. | |
| CN205411711U (en) | Vegetarian diet hole sealing capsule for gastrointestinal tract controlled release | |
| MISTRY et al. | Formulation and evaluation of floating drug delivery system | |
| JPH02504145A (en) | Enzyme-controlled drug release pellets | |
| CN213523777U (en) | Acid-resistant slow-release oral probiotic crystal ball structure | |
| Saxena et al. | Floating microspheres as drug delivery system | |
| Rajak et al. | Gastroretentive floating drug delivery system: an approach in gastroretentive drug delivery | |
| CN101249081A (en) | Administer orally controlled release drug administration pharmaceutical tablet | |
| CN101181226A (en) | System for slowing and controlling to release gas bag floationg | |
| JP5250285B2 (en) | Oral dressing, edible container and oral product using them | |
| CN102641286A (en) | Compound omeprazole dry suspension and preparation method thereof | |
| CN101658482A (en) | Low molecular chondroitin sulfate oral preparation, preparation method thereof and use thereof | |
| CN103169683B (en) | Sodium ilaprazole enteric orally disintegrating tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200213 Address after: 2 / f 7, No. 296, Section 2, Zhongshan Road, Zhonghe District, Xinbei, Taiwan, China Co-patentee after: Desheng Biotechnology Co.,Ltd. Patentee after: ANSHENG BIOLOG TECHNOLOGY Co.,Ltd. Address before: 116, Sicun Road, dundongli, Houli District, Taizhong City Patentee before: MEIJIASHENG PEPTIDE TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200723 Address after: 14-22 Quanzhou Road, Houli District, Taichung, Taiwan, China Co-patentee after: Desheng Biotechnology Co.,Ltd. Patentee after: bio-Peptide Enhancer Tech Inc.,Ltd. Address before: 2 / f 7, No. 296, Section 2, Zhongshan Road, Zhonghe District, Xinbei, Taiwan, China Co-patentee before: Desheng Biotechnology Co.,Ltd. Patentee before: ANSHENG BIOLOG TECHNOLOGY Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150204 |